


## PHARMACEUTICAL 2019

## Cogent Biosciences Inc. Rank 171 of 371







## PHARMACEUTICAL 2019

## Cogent Biosciences Inc. Rank 171 of 371



The relative strengths and weaknesses of Cogent Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cogent Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Cogent Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -132%, being 199% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	81,002
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,945
Liabilities, Non-Current	0
Other Assets	1,674
Other Compr. Net Income	4.0
Other Expenses	0
Other Liabilities	748
Other Net Income	1,473
Property and Equipment	3,251
Research and Development	38,285
Revenues	9,734
Selling, General and Administrative Expense	7,454

Output Variable	Value in 1000 USD
Assets	85,927
Liabilities	25,693
Expenses	45,739
Stockholders Equity	60,234
Net Income	-34,532
Comprehensive Net Income	-34,530
Economic Capital Ratio	-132%